Published in Sleep Med on December 08, 2010
Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain (2011) 1.35
Amygdala lesions reduce cataplexy in orexin knock-out mice. J Neurosci (2013) 1.09
Narcolepsy: neural mechanisms of sleepiness and cataplexy. J Neurosci (2012) 1.07
Role of the medial prefrontal cortex in cataplexy. J Neurosci (2013) 0.93
Clinical and polysomnographic course of childhood narcolepsy with cataplexy. Brain (2013) 0.87
REM Sleep at its Core - Circuits, Neurotransmitters, and Pathophysiology. Front Neurol (2015) 0.81
Treatment paradigms for cataplexy in narcolepsy: past, present, and future. Nat Sci Sleep (2015) 0.79
Laughter and MIRTH (Methodical Investigation of Risibility, Therapeutic and Harmful): narrative synthesis. BMJ (2013) 0.78
Orexin Neurons Respond Differentially to Auditory Cues Associated with Appetitive versus Aversive Outcomes. J Neurosci (2016) 0.76
Sleep dynamics beyond traditional sleep macrostructure. Sleep (2013) 0.76
The anatomical, cellular and synaptic basis of motor atonia during rapid eye movement sleep. J Physiol (2016) 0.75
Narcolepsy with Cataplexy in an Elderly Woman. J Gen Intern Med (2015) 0.75
The Roles of Dopamine and Hypocretin in Reward: A Electroencephalographic Study. PLoS One (2015) 0.75
Narcolepsy Type 1 and Idiopathic Generalized Epilepsy: Diagnostic and Therapeutic Challenges in Dual Cases. J Clin Sleep Med (2015) 0.75
GABAergic Neurons of the Central Amygdala Promote Cataplexy. J Neurosci (2017) 0.75
The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol (2002) 4.03
Hypocretin (orexin) loss in Parkinson's disease. Brain (2007) 1.98
Transesophageal echocardiography is superior to transthoracic echocardiography in management of patients of any age with transient ischemic attack or stroke. Stroke (2006) 1.93
Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial. Lancet Neurol (2013) 1.71
ImmunoChip study implicates antigen presentation to T cells in narcolepsy. PLoS Genet (2013) 1.55
Cataplexy: 'tonic immobility' rather than 'REM-sleep atonia'? Sleep Med (2002) 1.51
Hypocretin/orexin disturbances in neurological disorders. Sleep Med Rev (2008) 1.45
The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns. Vaccine (2012) 1.41
Narcolepsy: immunological aspects. Sleep Med Rev (2008) 1.28
Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity. Obes Res (2003) 1.19
Sleep and circadian rhythm alterations correlate with depression and cognitive impairment in Huntington's disease. Parkinsonism Relat Disord (2010) 1.18
Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study. J Sleep Res (2013) 1.07
Psychotic symptoms in narcolepsy: phenomenology and a comparison with schizophrenia. Gen Hosp Psychiatry (2009) 1.06
Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol Aging (2011) 1.05
Altered skin-temperature regulation in narcolepsy relates to sleep propensity. Sleep (2006) 1.05
Focusing on vigilance instead of sleepiness in the assessment of narcolepsy: high sensitivity of the Sustained Attention to Response Task (SART). Sleep (2006) 1.04
Is motor inhibition during laughter due to emotional or respiratory influences? Psychophysiology (2004) 1.02
Increased heart rate variability but normal resting metabolic rate in hypocretin/orexin-deficient human narcolepsy. J Clin Sleep Med (2008) 0.99
Effect of sodium oxybate on growth hormone secretion in narcolepsy patients and healthy controls. Am J Physiol Endocrinol Metab (2011) 0.99
Reward-seeking behavior in human narcolepsy. J Clin Sleep Med (2011) 0.96
The number of hypothalamic hypocretin (orexin) neurons is not affected in Prader-Willi syndrome. J Clin Endocrinol Metab (2005) 0.95
Narcolepsy as an adverse event following immunization: case definition and guidelines for data collection, analysis and presentation. Vaccine (2012) 0.93
Assessment of sleep and sleepiness in Parkinson disease. Sleep (2003) 0.93
Manipulation of core body and skin temperature improves vigilance and maintenance of wakefulness in narcolepsy. Sleep (2008) 0.88
Possible confusion between primary hypersomnia and adult attention-deficit/hyperactivity disorder. Psychiatry Res (2006) 0.88
Anti-Ri antibody positive opsoclonus-myoclonus in a male patient with breast carcinoma. J Neurol (2002) 0.87
Voxel-based morphometry in hypocretin-deficient narcolepsy. Sleep (2003) 0.87
Association between hypocretin-1 and amyloid-β42 cerebrospinal fluid levels in Alzheimer's disease and healthy controls. Curr Alzheimer Res (2012) 0.85
Hypocretin/orexin and sleep: implications for the pathophysiology and diagnosis of narcolepsy. Curr Opin Neurol (2002) 0.84
Narcolepsy and pregnancy: a retrospective European evaluation of 249 pregnancies. J Sleep Res (2013) 0.84
Sustained attention to response task (SART) shows impaired vigilance in a spectrum of disorders of excessive daytime sleepiness. J Sleep Res (2011) 0.83
Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy. J Neurol (2007) 0.82
Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy. J Neuroimmunol (2006) 0.82
Severe fatigue in narcolepsy with cataplexy. J Sleep Res (2011) 0.81
Altered setting of the pituitary-thyroid ensemble in hypocretin-deficient narcoleptic men. Am J Physiol Endocrinol Metab (2004) 0.81
Hypernatremia from a hunger strike as a cause of osmotic myelinolysis. Neurology (2005) 0.80
Time- and state-dependent analysis of autonomic control in narcolepsy: higher heart rate with normal heart rate variability independent of sleep fragmentation. J Sleep Res (2014) 0.80
Corticospinal excitability during laughter: implications for cataplexy and the comparison with REM sleep atonia. J Sleep Res (2004) 0.79
Hypocretin (orexin) loss and sleep disturbances in Parkinson's Disease. Brain (2007) 0.79
CSF hypocretin-1 levels are normal in patients with amyotrophic lateral sclerosis. Amyotroph Lateral Scler (2009) 0.79
Somatotropic axis in hypocretin-deficient narcoleptic humans: altered circadian distribution of GH-secretory events. Am J Physiol Endocrinol Metab (2002) 0.78
The influences of task repetition, napping, time of day, and instruction on the Sustained Attention to Response Task. J Clin Exp Neuropsychol (2014) 0.78
Plasma total ghrelin and leptin levels in human narcolepsy and matched healthy controls: basal concentrations and response to sodium oxybate. J Clin Sleep Med (2013) 0.78
Re: Silber MH, Krahn LE, Olson EJ. Diagnosing narcolepsy: validity and reliability of new diagnostic criteria. Sleep Med. 2002 Mar;3(2):109-13. Sleep Med (2002) 0.77
Sodium oxybate is an effective and safe treatment for narcolepsy. Sleep Med (2009) 0.76
Altered circadian rhythm of melatonin concentrations in hypocretin-deficient men. Chronobiol Int (2012) 0.76
Sodium oxybate increases prolactin secretion in narcolepsy patients and healthy controls. Eur J Endocrinol (2010) 0.76
Screening for anti-ganglioside antibodies in hypocretin-deficient human narcolepsy. Neurosci Lett (2003) 0.76
Cataplexy leading to the diagnosis of Niemann-Pick disease type C. Pediatr Neurol (2006) 0.76
A patient with narcolepsy with cataplexy and multiple sclerosis: two different diseases that may share pathophysiologic mechanisms? Sleep Med (2013) 0.75
Intranasal hypocretin-1: making sense of scents? Sleep Med (2011) 0.75
Month of birth is not a risk factor for narcolepsy with cataplexy in the Netherlands. J Sleep Res (2011) 0.75
Impaired sustained attention in adult patients with type 1 diabetes is related to diabetes per se. Diabetes Metab Res Rev (2014) 0.75
Restless legs syndrome. BMJ (2012) 0.75
Eating Decisions Based on Alertness Levels after a Single Night of Sleep Manipulation: A Randomized Clinical Trial. Sleep (2016) 0.75
Psychiatric comorbidity and aspects of cognitive coping negatively predict outcome in cognitive behavioral treatment of psychophysiological insomnia. Behav Sleep Med (2014) 0.75